Analyst Joseph Pantginis of H.C. Wainwright reiterated a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report), retaining the ...

Bayer announced today initiation of dosing in a Phase I first-in-human clinical study with 225 Ac-PSMA-Trillium (BAY 3563254), a next-generation targeted alpha therapy. The investigational candidate, ...

The firm’s stock price fluctuated 12.26% within the last five trades and 17.18% within the last 30 trades, which was a significant change from the beginning of this year. Despite the fact that the ...

Maxim Group analyst Jason McCarthy maintained a Buy rating on Actinium Pharmaceuticals (ATNM – Research Report) yesterday and set a price ...

Actinium Pharmaceuticals is a fantastic biotech company with a promising solution for a subset of AML patients. See why ATNM ...

The Phase II segment of the AlphaBreak trial is anticipated to conclude enrolment of around 60 patients by the end of this ...

Boomi today announced the acquisitions of APIIDA’s federated API management business and API management assets from ...

Bengaluru-based SaaS startup Knit has bagged $1 Mn in a seed funding round led by early-stage venture capital firm Endiya Partners, with participation from Axilor Ventures and unnamed angel investors.

Actinium Pharmaceuticals shares are trading higher after the company announced full data results from the pivotal Phase 3 SIERRA trial in patients with active, relapsed or refractory acute myeloid ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...